List view / Grid view
20 March 2017 | By Niamh Marriott, Junior Editor
Debiopharm International, a Swiss-based company, part of Debiopharm Group, announced that triptorelin 6-month formulation (Decapeptyl and Pamorelin 22.5 mg) received approval for the treatment of central precocious puberty (CPP) in 22 European countries, where the 6-month formulation has already been registered for the treatment of prostate cancer. Triptorelin is the…
Thermo Fisher Scientific Inc., the world leader in serving science, announced that it has acquired Core Informatics, which provides a leading cloud-based platform supporting scientific data management.
17 March 2017 | By Honeywell
Honeywell announced the launch of its first series of Hydranal™ double-certified reference materials (CRM) for Karl Fischer Titration...
17 March 2017 | By Honeywell
Honeywell announced the launch of a new business, Honeywell Research Chemicals, that will now include several brands and solvent and inorganic chemical products that were acquired from Sigma-Aldrich in December 2015...
17 March 2017 | By F.P.S. Food and Pharma Systems Srl
At Interphex (21-23 March in New York, USA), FPS will show his last innovations in micronization and milling technologies, for pharmaceutical, cosmetic and chemical applications...
17 March 2017 | By Niamh Marriott, Junior Editor
In a new study, advanced metastatic melanoma cancer patients that had become resistant to their BRAF-targeted treatment were given a retreatment...
17 March 2017 | By Niamh Marriott, Junior Editor
AstraZeneca’s Phase III SOLO-2 trial demonstrated a significant improvement in progression-free survival (PFS) in germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer patients treated with Lynparza (olaparib) tablets (300mg twice daily) compared with placebo in the maintenance setting. The trial met its primary endpoint of investigator assessed PFS (HR 0.30; 95%…
16 March 2017 | By Syrris
Syrris’ state-of-the-art Orb batch reactors are designed by chemists for chemists, ensuring they perfectly meet the demands of your work...
16 March 2017 | By Niamh Marriott, Junior Editor
PharmaJet has partnered with Serum Institute of India to commercialise needle-free delivery of the MMR vaccine using the Stratis 0.5ml needle-free system...
15 March 2017 | By Niamh Marriott, Junior Editor
Patients are set to benefit from more rapid access to the most cost-effective treatments after proposed changes to the NICE drug evaluation process were approved...
15 March 2017 | By Steve Bremer, Managing Editor
Tumour therapy, particularly in the case of multidrug resistant cancers, could be significantly enhanced by using siRNA to down-regulate the production...
15 March 2017 | By Niamh Marriott, Junior Editor
This collaboration is aimed at jointly developing and commercialising new liquid biopsy RAS biomarker tests for metastatic colorectal cancer (mCRC)...
15 March 2017 | By Niamh Marriott, Junior Editor
Moderate-to-severe psoriasis patients treated with Cosentyx (secukinumab) rapidly regain clear skin following relapse during a treatment pause...
14 March 2017 | By Niamh Marriott, Junior Editor
A new health economic analysis of two Phase 3b trials has demonstrated that Novo Nordisk's Tresiba is a cost-effective option for diabetes...
14 March 2017 | By Niamh Marriott, Junior Editor
Sandoz, a Novartis division, presented data for its proposed biosimilar adalimumab, GP2017, showing that their Phase III study met its primary endpoint...
